Bansal Arvind K, Kumar Dinesh
Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Sector-67, S. A. S. Nagar, Punjab 160062, India.
Pharmaceutical Solid-State Research Laboratory, Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi 221005, India.
Mol Pharm. 2025 Jul 7;22(7):3523-3529. doi: 10.1021/acs.molpharmaceut.5c00534. Epub 2025 May 29.
The pharmaceutical industry not only plays a crucial role in the healthcare system but also contributes significantly to the economy of a country. It is interesting to note that in 2024, a Danish pharmaceutical company held the title of Europe's most valuable company. Novo Nordisk, riding on popularity of a weight-loss drug, had a valuation of $600 billion in 2024, outweighing the GDP of Denmark , , 2049. Indian companies have achieved global recognition in generics, thus earning India the title of the "pharmacy of the world". This position was further strengthened during the COVID-19 pandemic when India supported the global needs with its high-capacity manufacturing and efficient supply chain management. However, despite these awards, the total valuation of the Indian pharmaceutical market, including its export values, is less than $100 billion. This highlights the focus of Indian pharmaceutical companies on generics, which generally generates less revenue with high volumes , 9285. In contrast, innovative products can generate a high revenue and accelerate economic growth. Innovative companies spend a good amount of their funds on research and development. It is well-recognized that a synergy between academic research institutions and pharmaceutical companies supports innovative outcomes , , 1-12. In this perspective, we discuss the prominent areas of pharmaceutical research in Indian academia and also analyze the status of solid-state pharmaceutics (SSP) and pharmaceutical crystal engineering research. The article discusses the evolution of research in SSP, its status, and future prospects. Authors emphasize the need for improvement of the research ecosystem for SSP, thus ensuring availability of optimal human resources for this critical component of the pharmaceutical industry. There is a need to create a "solid-state pharmaceutics research cluster" in India to accelerate the research and support the growth of the Indian pharmaceutical industry.
制药行业不仅在医疗保健系统中发挥着关键作用，而且对一个国家的经济也有重大贡献。值得注意的是，2024年，一家丹麦制药公司成为欧洲最具价值的公司。诺和诺德公司凭借一种减肥药物的知名度，在2024年的估值达到6000亿美元，超过了丹麦2049年的国内生产总值。印度公司在仿制药领域获得了全球认可，因此印度赢得了“世界药房”的称号。在新冠疫情期间，印度凭借其高产能制造和高效的供应链管理满足全球需求，这一地位得到了进一步巩固。然而，尽管有这些成就，包括出口价值在内的印度制药市场总估值仍不到1000亿美元。这凸显了印度制药公司对仿制药的专注，仿制药通常量大但收入较低。相比之下，创新产品可以带来高收入并加速经济增长。创新型公司将大量资金投入研发。众所周知，学术研究机构和制药公司之间的协同作用有助于产生创新成果。从这个角度出发，我们讨论了印度学术界制药研究的突出领域，并分析了固态药剂学（SSP）和药物晶体工程研究的现状。本文讨论了SSP研究的演变、现状和未来前景。作者强调需要改善SSP的研究生态系统，从而确保为制药行业这一关键组成部分提供最佳人力资源。有必要在印度创建一个“固态药剂学研究集群”，以加速研究并支持印度制药行业的发展。
